In an ambitious new endeavor, the Human Genome and Stem Cell Research Center (HUG-CELL) at the University of São Paulo (USP) is set to launch the “Our Genes” project, a comprehensive genetic screening initiative focused on identifying hereditary risks among Brazilian couples. This groundbreaking effort aims to pinpoint pairs who carry pathogenic variants in genes linked to recessive disorders, meaning conditions that manifest when a child inherits two defective copies of the same gene, one from each parent. Additionally, the project will screen for Fragile X syndrome, a prevalent inherited cause of intellectual disability. By inviting prospective parents to participate voluntarily, the initiative strives to empower them with vital genetic counsel and risk assessment information prior to conception.
Expertly coordinated by HUG-CELL, a FAPESP Research, Innovation, and Dissemination Center (RIDC), and closely collaborating with academic institutions such as the University of Brasília (UnB), the Federal University of Bahia (UFBA), and the Federal University of Espírito Santo (UFES), this project reflects a profound commitment to advancing precision medicine tailored to Brazil’s unique genetic landscape. Dr. Michel Satya Naslavsky, a leading researcher involved in the project, recently outlined the initiative’s scope during the prestigious FAPESP Week London symposium, emphasizing its dual goals of preventive health and scientific discovery.
The “Our Genes” screening program offers couples the option to be tested for a panel of genes associated with recessive disorders and Fragile X syndrome. Should both partners harbor harmful mutations in the same gene, their offspring face a statistically significant 25% chance of inheriting the disorder. This information will be delivered with comprehensive genetic counseling, enabling informed reproductive choices. The scientific rationale behind targeting such variants lies in the recessive inheritance mechanism, where the disease phenotype remains silent if only one allele is affected but emerges when both alleles carry mutations.
Beyond immediate clinical applications, the project aspires to establish an expansive genomic repository representing Brazil’s genetically diverse populations. This database will catalyze the development of polygenic risk scores specifically calibrated for Brazilians, enhancing the prediction accuracy for complex diseases like diabetes, hypertension, and cardiovascular conditions. Historically, polygenic models have been derived largely from European cohorts, neglecting the extensive racial and genetic admixture characteristic of Brazil. This oversight results in skewed risk assessments, underscoring the critical need for population-tailored genetic data.
Naslavsky articulates the limitations of global genomic resources like the UK Biobank, which, despite its impressive scale of half a million participants, includes over 90% individuals of European descent. The underrepresentation of admixed populations, such as Brazilians, in existing databases creates significant blind spots in genetic research and medical applications. Polygenic risk prediction, which aggregates thousands of subtle DNA variants, exhibits marked variability across different ancestries, often leading to erroneous risk stratification when European-centric models are applied to diverse populations.
This ancestral gap also severely impairs rare disease diagnosis. Public repositories like ClinVar, which catalog known genetic variants, lack comprehensive data on non-European genomic fragments, reducing diagnostic accuracy by a factor of three for individuals with significant admixture. The resultant clinical uncertainty and misdiagnosis underscore the urgent imperative to generate indigenous genomic data reflecting Brazil’s complex genetic milieu. Only through such data sovereignty can precision medicine initiatives be responsibly and effectively implemented within the country’s universal health system, SUS.
Responding to this necessity, HUG-CELL pioneered the Brazilian Online Mutation Archive (ABraOM) in 2017, a vital public resource cataloging benign genetic variants prevalent in healthy elderly Brazilians. This dataset functions as a powerful filter in diagnostic workflows, distinguishing harmless polymorphisms from truly pathogenic mutations. With its 1,170 genomes, ABraOM remains the largest census-based genomic database in Brazil, facilitating accurate variant interpretation and expediting disease gene discovery. However, to truly capture Brazil’s genetic variability, an exponential scaling of genomic sequencing efforts is indispensable.
In alignment with this vision, the Brazilian Ministry of Health launched the Genoma SUS project in 2023, integrating nine laboratories nationwide and sequencing over 21,000 complete genomes to date. This initiative aims to catalog an additional 50,000 genomes within two years, with FAPESP funding 15,000 of these sequences from São Paulo alone. By creating a robust genomic infrastructure decentralizing data collection and analysis across all regions, Genoma SUS will provide a critical foundation for integrating genomic medicine into public health on a national scale.
The enormity and reach of Brazil’s public health system make it uniquely suited to capitalize on such investments in genomics. Comprehensive, population-representative genetic databases enable tailored diagnostic strategies, predictive modeling, and targeted treatments within the SUS framework, avoiding reliance on foreign data that inadequately captures Brazil’s ancestral heterogeneity. Naslavsky asserts that this approach is indispensable for the equitable and effective dissemination of precision medicine benefits throughout the country.
At the heart of the “Our Genes” initiative lies a profound principle of data sovereignty. Naslavsky advocates prioritizing public health interests in the management and utilization of genomic information, ensuring that scientific returns primarily benefit SUS and broader public health objectives. This stance resonates ethically, given the collective societal investment in data generation and the necessity to safeguard sensitive genetic information within transparent, equitable governance structures, fostering trust and accessibility.
Moreover, beyond its narrow clinical imperative, genomic research centered on Brazil’s admixed population presents unprecedented opportunities to uncover novel biological pathways underlying complex traits and diseases. For example, investigations into Alzheimer’s disease risk alleles and lipid metabolism variants within this diverse genetic backdrop may reveal alternative molecular mechanisms absent in homogeneous populations. Such discoveries carry transformative potential for identifying new therapeutic targets with global ramifications.
Ultimately, the “Our Genes” project exemplifies a paradigm shift towards inclusive, context-specific genomic medicine, tailored to the intricate population genetics of Brazil. By marrying cutting-edge research with public health imperatives and emphasizing data sovereignty, this initiative pioneers a blueprint for other nations confronting similar admixture and diversity challenges. Through its rigorous genetic screening, comprehensive data generation, and principled governance models, the project envisions reducing hereditary disease burden while accelerating biomedical innovation beneficial for both Brazil and the wider world.
For further information and ongoing updates on this initiative and associated projects, interested readers and researchers can refer to the detailed coverage of FAPESP Week London at fapesp.br/week/2026/london.
Subject of Research: Genetic screening for recessive disorders and Fragile X syndrome; population genomics; precision medicine implementation in Brazil.
Article Title: Brazil’s “Our Genes” Project: Pioneering Genomic Screening and Data Sovereignty to Transform Public Health
News Publication Date: (Not specified in the source text)
Web References:
- Human Genome and Stem Cell Research Center (HUG-CELL): https://www.genoma.ib.usp.br/en
- FAPESP Week London: https://fapesp.br/week/2026/london
- UK Biobank: https://www.ukbiobank.ac.uk/
- ClinVar Genetic Variants Repository: https://www.ncbi.nlm.nih.gov/clinvar/
- Genoma SUS Project: https://genomassus.com.br/
Keywords: Genetic disorders, recessive inheritance, Fragile X syndrome, Brazilian genomics, precision medicine, polygenic risk scores, data sovereignty, public health genomics, admixture, genetic databases, ABraOM, Genoma SUS
